Suspension of Humalog supplies to Russia may cause problems

The Swiss company Swixx BioPharma has stopped the supplies of Humalog insulin (insulin lispro) to Russia due to the decision of its manufacturer, the American pharma major Eli Lilly (NYSE: LLY), The Pharma Letter’s local correspondent reports.

According to Swixx BioPharma, which is distributing the drug in Russia, the remaining stocks of the drug are now being sold out, and new supplies are not expected. That may pose a threat to the shortage of the drug in the Russian market. In accordance with the existing Russian legislation, drugmakers must warn the Russian drug regulator Roszdravnadzor about the cessation of supplies a year before the planned date.

However, according to representatives of the regulator, currently Russia still has some reserves of the drug, which are estimated at more than a million packages, and corresponds to the annual need for the drug. In addition, in 2024, the Russian manufacturer, JSC Pharmsyntez-Nord, began producing such insulin.